A5073499997- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Urticaria and Related Conditions
- Autoimmune and Inflammatory Disorders
- Autoimmune Bullous Skin Diseases
- Nail Diseases and Treatments
- Contact Dermatitis and Allergies
- Dermatological diseases and infestations
- Eosinophilic Disorders and Syndromes
- Cutaneous lymphoproliferative disorders research
- Pneumocystis jirovecii pneumonia detection and treatment
- Hair Growth and Disorders
- Stoma care and complications
- Tuberous Sclerosis Complex Research
- Phytoestrogen effects and research
- Anorectal Disease Treatments and Outcomes
- Chemotherapy-related skin toxicity
- Wound Healing and Treatments
- Oral Health Pathology and Treatment
- Poxvirus research and outbreaks
- Insects and Parasite Interactions
- Tumors and Oncological Cases
- PI3K/AKT/mTOR signaling in cancer
- Autism Spectrum Disorder Research
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2017-2024
Ospedale Maggiore
2019-2023
University of Milan
2016-2021
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2021
University of Molise
2021
University of Bologna
2014-2015
Background: The clinical features of adult-onset atopic dermatitis (AD) are heterogeneous and the diagnosis can be a challenge. A new biologic drug (dupilumab) has been approved for moderate to severe AD in adult patients. efficacy safety have demonstrated trials, but these studies do not reflect conditions daily practice consider different manifestations AD. Objectives: Analyzing dupilumab activity real-world setting comparing its on phenotypes. Methods: We retrospectively evaluated 221...
Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data 117 severe AD patients treated with dupilumab were collected. At and at weeks 4 16, disease severity assessed through Eczema Area Severity Index (EASI) quality life Dermatology Life Quality (DLQI) questionnaire, Patient-Oriented Measure (POEM), Hospital Anxiety Depression Scale (HADS), Peak...
Transient eosinophilia is not uncommon in patients with moderate-to-severe atopic dermatitis (AD) treated dupilumab.A retrospective, single center, observational study was conducted to assess the difference terms of absolute eosinophil count (AEC) change at 4 months and 12 months, relative baseline, predefined subgroups affected by AD dupilumab.Complete data for 373, 289 210 were available respectively. Patients a history conjunctivitis (n = 152) had greater increases AEC as compared those...
Atopic dermatitis (AD) is a common chronic multifactorial dermatosis that can occur through different clinical phenotypes although all exhibit identical pathogenetic mechanisms such as the prurigo nodularis (PN)-like phenotype.Here, we described 11 patients with PN-like AD treated dupilumab, human monoclonal IgG4 antibody inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13). Efficacy outcomes were performed at baseline, first fourth month after starting treatment. We collected scores...
The aim of this study was to detect demographic and clinical factors associated with affective symptoms quality life in patients severe atopic dermatitis. First, one-way analyses variance correlations were performed compare a large set qualitative quantitative variables. Three final multivariable regression models performed, depression/anxiety subscales Dermatology Life Quality Index scores as dependent variables, the that statistically significant on univariate independent ones. More...
Atopic dermatitis (AD) is an inflammatory skin disease. Patients with AD are prone to develop anxiety and mood disorders. Aim of this study investigate if treatment dupilumab may improve mental health status patients affected by AD. A total 66 severe were included: 24 subjects candidate or have just started (one month) dupilumab, 42 been in for one year. 25.8%, 30.3%, 45.5% the sample showed, respectively, clinically significant anxiety, depression, symptoms Internet addiction. resulted more...
Background: The main objective was to analyze patient-reported outcomes (PRO) trends over a four-year period in severe atopic dermatitis (AD) patients treated with dupilumab. Methods: data from 126 receiving dupilumab for at least 48 months were collected. clinical scores assessed included the Eczema Area and Severity Index (EASI), Pruritus Numerical Rating Scale (NRS), Sleep NRS, Patient-Oriented Measure (POEM), Dermatology Life Quality (DLQI), Atopic Dermatitis Control Tool (ADCT)....
"Treatment of hookworm-related cutaneous larva migrans with topical ivermectin." Journal Dermatological Treatment, 28(3), p. 263
Patients with a stoma are at risk of developing peristomal skin complications (PSCs) that can negatively impact their quality life. This study aims to identify potential factors for dermatitis, pruritis/xerosis, infections, and ulcerations among patients evaluate preventive measures. cross-sectional involved data regarding 232 Italian stoma. A questionnaire was used collect patient characteristics, comorbidities, management data. The most frequent PSCs observed were dermatitis...
Background: Atopic Dermatitis (AD) is a prevalent inflammatory skin disease whose course often complicated by the presence of concomitant anxiety and depressive disorders. Dupilumab has been demonstrated to be largely effective in AD. The aims present study were (1) verify effectiveness 2-year dupilumab treatment on symptoms patients affected AD (2) identify predictors persistence psychiatric despite maintenance with dupilumab. Methods: A total 331 severe assessed at baseline different times...
Atopic dermatitis (AD) is a common chronic-relapsing inflammatory skin disease hallmarked by epidermal barrier dysfunction, increased transepidermal water loss (TEWL) and decreased hydration. Recent findings on the T helper 2 (Th2)-driven pathogenesis of AD have led to development dupilumab, monoclonal antibody directed against interleukin-4 interleukin-13 that has been demonstrated be effective in treatment moderate-to-severe AD. The effect dupilumab however, not yet adequately...
Rosacea fulminans is a rare and severe inflammatory dermatosis which affects predominantly childbearing women. It characterized by sudden onset it usually localizes exclusively on the centrofacial areas, presenting with numerous fluctuant nodules papules may coalesce. Treatment isotretinoin in combination topical systemic corticosteroids successful. Clearance of lesions be obtained under treatment no or minimal scarring outcomes. Due to incidence its pathophysiological mechanisms, diagnosis...
This item has no abstract. Follow the links in page to access full text.
Alopecia areata (AA), an autoimmune disease with a relapsing-remitting course, represents the second cause of non-scarring alopecia worldwide and is associated several comorbidities, notably atopic dermatitis (AD). In particular, AD related to its more severe forms totalis (AT) universalis (AU) [Nat Rev Dis Primers. 2017;3:17011]. Considering that AA has been classified as T helper 1-driven disease, whereas prototypical 2 (Th2)-driven skin disorder, recent studies suggest these may underlie...
article: Effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: a preliminary report real-world data - Italian Journal Dermatology Venereology 2022 April;157(2):211-3 Minerva Medica Journals
Endolimax nana is a commensal protozoan of the colon. We report case chronic urticaria associated with E. in 34-year-old Italian woman. The patient suffered from abdominal pain, diarrhoea and weight loss. disease appeared after trip to Vietnam. Laboratory examinations showed mild blood eosinophilia. Three coproparasitological were positive for cysts nana. was successfully treated two courses metronidazole (2 g/day 10 days each). No antihistamines used. examinations, carried out at end...
Atopic diseases affect millions of patients worldwide, with the greatest impact on children and young adults. Type 2 inflammation is underlying mechanism for development barrier defect in all atopic as asthma, dermatitis, chronic rhinosinusitis nasal polyps, eosinophil esophagitis. In our practice we deal every day a lot treatment dupilumab AD realized that almost these were affected by one or more allergic diseases. Based this real life experience decided to create multidisciplinary group...